Quick Answer
Compass Therapeutics, Inc. reported Cash and Equivalents of $30.64 million for fiscal year 2025.
Compass Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $30.64M | -29.5% |
| 2024 | $43.48M | +79.5% |
| 2023 | $24.23M | -30.7% |
| 2022 | $34.95M | -75.8% |
| 2021 | $144.51M | +207.0% |
| 2020 | $47.08M | +1256936.0% |
| 2020 | $3.7K | -100.0% |
| 2019 | $25.30M | +519895.9% |
| 2019 | $4.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $46.21M | +138.2% | +102.2% |
| June 30, 2025 | $22.86M | +17.8% | -44.3% |
| March 31, 2025 | $41.05M | -5.6% | -5.6% |
| December 31, 2024 | $43.48M | +79.5% | +124.1% |
| September 30, 2024 | $19.40M | -36.2% | +0.0% |
| June 30, 2024 | $19.40M | +0.7% | -55.4% |
| March 31, 2024 | $43.48M | +60.9% | +79.5% |
| December 31, 2023 | $24.23M | -30.7% | -20.4% |
- Compass Therapeutics, Inc. showed a decrease of -29.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Compass Therapeutics, Inc.’s cash and equivalents has grown by 629637.0% (from $4.9 thousand to $30.64 million).
- The most recent figure is from Compass Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: